EHA 2019: ADMIRAL Trial Establishes Major Role for Gilteritinib in Relapsed/Refractory Acute Myeloid Leukemia
Gilteritinib offered higher overall response and survival than salvage chemotherapy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.